Patients with cancer are at high risk for severe COVID-19 diseases and show impaired
immune responses after vaccination. Specifically, levels of neutralizing antibodies
against variants of concern, including Delta and Omicron, are lower in cancer patients.
Fourth vaccination dose or administration of monoclonal neutralizing antibodies, such
as tixagevimab and cilgavimab, is being considered, although data supporting this
strategy are limited, especially for currently circulating variants, such as BA.4.
The Medical University Vienna analyzed the variant-specific humoral immunity after
active and passive SARS-CoV-2 immunization in 72 patients with haemato-oncological
diseases by comparing antibody levels after the third and fourth vaccinations or
administration of tixagevimab and cilgavimab in patients with cancer.
The webinar ist presented by Maximilian Mair, University Department of Internal Medicine I.
Participation is free.